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Background: Long noncoding RNAs (lncRNAs) have recently emerged as important regulators in governing
fundamental biological processes, and many of which are likely to have functional roles in tumorigenesis.
Maternally expressed gene 3 (MEG3) gene encodes a lncRNA whose expression is lost in an expanding list of
primary human tumors and tumor cell lines, however its biological role and regulatory mechanism in gastric cancer
(GC) development and progression are poorly defined.
Methods: Quantitative RT-PCR analysis was used to determine whether aberrant MEG3 expression was associated
with GC patients pTNM stage and pM state. Furthermore, the effect of ectopic expression of MEG3 on cell proliferation,
migration, invasion and cell apoptosis was assessed by using CCK-8, wound healing, transwell invasion assays and flow
cytometric analysis, respectively, in GC cell lines HGC-27 and MGC-803. Moreover, the competing endogenous RNA
(ceRNA) activity of MEG3 on miR-181a was investigated via luciferase reporter assay and immunoblot analysis.
Results: MEG3 is decreased in GC patients and cell lines, and its expression was associated with metastatic GC.
Furthermore, ectopic expression of MEG3 in HGC-27 and MGC-803 cells inhibited cell proliferation, migration, invasion,
and promoted cell apoptosis, which might be due to MEG3 sequestering oncogenic miR-181 s in GC cells.
Furthermore, MEG3 could up-regulated Bcl-2 via its competing endogenous RNA (ceRNA) activity on miR-181a.
Conclusions: These findings suggest that lncRNA MEG3, a ceRNA of miR-181 s, could regulate gastric carcinogenesis
and may serve as a potential target for antineoplastic therapies.
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The ENCODE (encyclopedia of DNA elements) project
showed that ~80 % of the human genome is transcribed
to RNA, with only ~2 % being responsible for protein cod-
ing. According to their size, non-coding RNAs (ncRNAs)
are classified into small ncRNAs and long ncRNAs
(lncRNAs). Small ncRNAs include siRNAs, piRNAs, and
miRNAs that have a length of less than 200 nucleotides
(nt). LncRNAs are greater than 200 nt in length, fre-
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range of cellular functions such as development, differen-
tiation, and cell fate as well as disease pathogenesis, caus-
ing a paradigm change in our understanding of gene
regulation [1–3]. For example, the metastasis-associated
lungadenocarcinoma transcript1 (MALAT1), also known
as NEAT2, has been implicated in several studies as hav-
ing an important role in metastasis [4–6]. H19 dysregula-
tion has also been implicated in a variety of other cancers,
as colorectal cancer, hepatocellular carcinoma, breast can-
cer, and bladder cancer [7–11]. Additionally, the HOX
antisense intergenic RNA (HOTAIR) was shown to be
overexpressed up to 2000 fold in breast cancer metastases,
with its expression being a significant predictor of metas-
tasis and death independent of other risk factors such as
tumor size, stage, and hormone receptor status [12–14].is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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was found to have increased expression in metastatic
colorectal cancer patient tumor samples. The lncRNA
gastric cancer associated transcript 1 (GACAT1), was
found to be expressed at lower levels in gastric can-
cer tissues compared to corresponding normal tissues
[15, 16]. Identification of differential expression, while
extremely useful, is only the first step in the elucida-
tion of the lncRNA-based molecular mechanisms cap-
able of regulating tumorigenesis. Exploration of the
function and involvement of lncRNA in gene expres-
sion may become a key development in exploring the
molecular mechanisms of cancer.
Gastric cancer (GC) ranks the fourth most commonly
diagnosed cancer and the second lethal malignancy
worldwide, and is the most common gastrointestinal malig-
nancy in East Asia, Eastern Europe, and parts of Central
and South America [17–19]. GC is diagnosed at advanced
stage accompanied by malignant proliferation and metasta-
sis. In spite of the progress in chemotherapy, radiotherapy
and surgical techniques for GC in recent years, the survival
rate of GC patients remains unsatisfactory [20]. Although
many oncogenes or tumor suppressors have been identified
as key players underlying tumorigenesis of GC, however, al-
most no commonly-accepted biomarkers have been estab-
lished to facilitate the comprehensive management of
patients [21, 22]. Therefore, the identification of the new
regulators and therapeutic targets for GC and a detailed
understanding of the molecular mechanisms underlying
gastric carcinogenesis will be important to understand the
molecular biology of tumor and its progression. The signifi-
cance of lncRNAs in human GC was realized by Yang and
colleagues elucidating the contributions of H19 to GC, sug-
gesting a link between lncRNAs and GC [7]. Following this
study, several groups focused on the aberrant expression of
lncRNAs during GC, and accumulating studies indicated
that specific lncRNAs had potential biological and clinical
relevance in GC [23]. Therefore, it is of great clinical value
to identify cancer-associated lncRNAs and investigate their
molecular and biological functions for GC prevention, diag-
nosis, and therapeutic targets.
In the current study, we showed that a lncRNA, mater-
nally expressed gene 3 (MEG3) is decreased in GC patients
and cell lines, and its expression was associated with meta-
static GC. We also showed that MEG3 inhibited GC cell
proliferation, migration and invasion by operating as a
competing endogenous RNA (ceRNA) for the miR-181
microRNA (miRNA) family. Furthermore, MEG3 affected
GC cell phenotypes in a miR-181 sites-dependent manner,
which occurs without changes in the levels of miR-181
isoforms, suggesting that MEG3 regulates miR-181 activ-
ity by altering miRNA targeting. B cell lymphoma-2
(Bcl-2) was subsequently validated as a downstream target
of MEG3 ceRNA function, and was important for MEG3to regulate GC progression. Taken together, these results
suggest that MEG3 could regulate gastric carcinogenesis




Gastric cancers and their morphologically normal tis-
sue (located >3 cm away from the tumor)were ob-
tained between November 2011 and November 2014
from 50 gastric cancer patients undergoing surgery at
Cancer Hospital of Chinese Academy of Medical Sciences.
Tissue samples were cut into two parts, one was fixed
with 10 % formalin for histopathological diagnosis, and
the other was immediately snap-frozen in liquid nitrogen,
and stored in liquid nitrogen until RNA extraction. This
group consisted of 38 males and 12 females with a median
age of 58 years (range, 32–69 years). The use of the tissue
samples for all experiments was approved by all the pa-
tients and by Ethics Committee of the institution.
Tissue RNA isolation and qRT-PCR
Total RNA was extracted from the cells and tissues using
Trizol reagent (Invitrogen, CA, USA), according to the
manufacturer’s instructions. RT-qPCR assay was conducted
to detect the level of RNA transcripts. Briefly, cDNA was
synthesised by M-MLV reverse transcriptase (Invitrogen)
from 5 ug of total RNA. Oligo (dT18) RT primer was used
for the reverse transcription of mRNA and lncRNA. Stem-
poop RT primer was used for the reverse transcription of
miR-181a. Quantitative RT-qPCR was performed on the
Bio-rad CFX96 real-time PCR System (Bio-rad, Foster City,
CA, USA) using KAPA PROBE FAST qPCR Kits (Kapa
Biosystems, MA, USA) and TaqMan probes (Invitrogen)
with the following cycling conditions: 95 °C for 10 min (ini-
tial denature); then 40 cycles of 95 °C for 15 sec, 60 °C for
60 sec. The miR-33b specific forward primer sequence was
designed on the basis of miRNA sequences obtained from
the miRBase database. Human GAPDH and U6 snRNA
were used for mRNA/lncRNA and miRNA normalization,
respectively.
Cell cultures and cell transfection
A total of 6 human gastric cancer cell lines MGC-803,
HGC-27, MKN-45, SGC-7901, BGC-823 and AGS were
examined in this study. The HGC-27, MKN-45, SGC-
7901 cell lines were provided by American Type Culture
Collection (ATCC; Manassas, VA, USA), and were main-
tained in RPMI 1640 medium (PAA) supplemented with
10 % FBS (PAA). The MGC-803, BGC-823 and AGS cell
lines were purchased from the Cell Resource Center of
Institute of Basic Medical Sciences, Chinese Academy of
Medical Sciences and Peking Union Medical College
(Beijing, China), and was propagated in Dulbecco’s
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gies, Germany), supplemented with 10 % fetal bovine serum
(FBS; PAA, Pasching, Austria) and streptomycin
(100 μg/ml), penicillin (100 U/ml). The human gas-
tric cancer cell lines HGC-27 and MGC-803 were
transfected with miRNA mimic, mimic control, miRNA
inhibitor, inhibitor control, (Scramble; GenePharma;
Shanghai, China) at a final concentration of 25 nmol/L
using DharmaFECT 1 (Dharmacon; USA) in accordance
with the manufacturer’s instructions. The same cells were
transfected with different MEG3 constructs at a final con-
centration of 2 μg/uL using Lipo2000 (Invitrogen; USA) in
accordance with the manufacturer’s instructions.
Cell proliferation assay
Hgc-27 and MGC-803 cells were incubated in 10 %
CCK-8 (DOJINDO, Japan) diluted in normal culture
medium at 37 °C until visual color conversion occurred.
Proliferation rates were determined at 0, 24, 48, 72,
96 hours after transfection. The absorbance of each well
was measured with a microplate reader set at 450nM and
630nM. All experiments were performed in quadruplicate.
Cell apoptosis assay
In order to detect the apoptosis of HGC-27 and MGC-
803 cells, flow cytometric analysis was applied with
Annexin V-FITC/PI Apoptosis Detection Kit (KeyGEN
Biotech, Nanjing, China) according to the manufac-
turer’s instructions. The acquisition and analysis were
performed using MoFlow (Beckman Coulter, Atlanta,
GA, USA).
Cell migration and invasion assays
HGC-27 and MGC-803 cells were grown to confluence
on 12-well plastic dishes and treated with miRNA
mimics or Scramble. Then 24 hours after transfection,
linear scratch wounds (in triplicate) were created on the
confluent cell monolayers using a 200 μL pipette tip. To
remove cells from the cell cycle prior to wounding, cells
were maintained in serum-free medium. To visualize mi-
grated cells and wound healing, images were taken at 0,
24, 48 hours. A total of ten areas were selected randomly
from each well and the cells in three wells of each group
were quantified.
For the invasion assays, after 24 hours transfection,
1 × 105 HGC-27or MGC-803 cells in serum-free media
were seeded onto the transwell migration chambers
(8 μm pore size; Millipore, Switzerland) which coated
with the upper chamber of an insert coated with Matrigel
(Sigma-Aldrich, USA). Media containing 20 % FBS were
added to the lower chamber. After 24 hours, the nonin-
vading cells were removed with cotton wool, Invasive cells
located on the lower surface of the chamber were stained
with May-Grunwald-Giemsa stain (Sigma-Aldrich, USA)and counted using a microscope (Olympus, Tokyo, Japan).
Experiments were independently repeated three times.
Luciferase reporter assay
HGC-27 cells were co-transfected with 0.4 μg of pMIR
constructs containing the wild type MEG3 or diverse
mutant MEG3, along with 0.02 μg of the pRL-TK con-
trol vector and miR-181a mimic or mimic control. Cells
were harvested 48 h post-transfection and assayed with
Dual Luciferase Assay (Promega, WI, USA) according to
the manufacturer’s instructions. All transfection assays
were carried out in triplicate.
Immunoblotting
Immunoblot analysis was carried out using standard
methods. Proteins were separated by 10 % SDS-PAGE, and
transferred onto PVDF membranes (Millipore Corporation,
Billerica MA, USA). Membranes were blocked overnight
with 5 % non-fat dried milk for 2 h and incubated with
anti-Bcl-2 antibody (Abcam, ab117115) at 1:2000 dilution;
anti-GAPDH antibody (Proteintech) at 1:50,000 dilution
overnight at 4 °C. After washing with TBST (10 mM Tris,
pH 8.0, 150 mM NaCl, and 0.1 % Tween20), the mem-
branes were incubated for 2 h at room temperature with
goat anti-rabbit antibody (Zsgb-bio, Beijing, China) at
1:20000.
RNA pull-down by MS2-MBP
Maltose-binding protein (MBP)-affinity purification was
used to identify miRNAs that associated with lncRNA
MEG3. The MS2-MBP protein was expressed and puri-
fied from E. coli following a protocol from the Steitz lab.
Three bacteriophage MS2 coat protein-binding sites
(5′-cgtacaccatcagggtacgagctagcccatggcgtacaccatcagggta
cgactagtagatctcgtacaccatcagggtacg-3’) were inserted down-
stream of MEG3 by site-directed mutagenesis using
Stratagene’s QuikChange Site-Directed Mutagenesis Kit.
To obtain miRNAs associated with MEG3, HGC-27 cells
were transfected with MS2-containing MEG3 constructs,
and 10 million cells were used for each immunoprecipita-
tion assay. The cells were harvested 48 h post-transfection
and subjected to RNA pull-down analysis as described
elsewhere.
Results
Aberrant expression of lncRNA MEG3 in human GC
tissues and cell lines
To determine the expression of lncRNA MEG3 in GC, q-
PCR analysis using TaqMan probes was conducted in 50
pairs of clinic GC tissue and matched adjacent normal tis-
sue samples. Among them, 35 cases (70 %) showed signifi-
cantly reduced level of MEG3 in tumor tissues compared
with their normal tissues, whereas only 8 cases (16 %)
showed up-regulated MEG3 level in GC (Fig. 1a). In
Fig. 1 The expression of MEG3 in GC tissues and cell lines. a The expression of level of MEG3 was detected in 50 GC patients by RT-qPCR. Data
was presented as fold change of GC tissues relative to adjacent normal regions; b Relative MEG3 expression level in GC tissues and adjacent normal
regions; c The Statistical analysis of the association between MEG3 level and pM stage (No metastasis and Metastasis); d The Statistical analysis of the
association between MEG3 level and pTNM stage (I, II, III and IV); e The relative level of MEG3 in GC cell lines (HGC-27,MGC-803, MKN-45,
SGC-7901, BGC-823 and AGS) relative to 8 normal control samples; For all quantitative results, the data are presented as the mean ± SEM,
and the error bars represent the standard deviation obtained from three independent experiments. *p < 0.05; **p < 0.01
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pared with adjacent normal tissues (Fig. 1b). To further
study the relationship between MEG3 level and clinicopath-
ological factors of GC, the expression of MEG3 in GC tis-
sues were statistically analyzed (non-parametric test).
Interestingly, we found that the lower MEG3 was associ-
ated with pM stage (Fig. 1c, p < 0.01, metastasis vs. non me-
tastasis) and pTNM stage (Fig. 1d, p < 0.01, stageIvs. IV;
p < 0.01, stage II vs. IV; p < 0.01, stage III vs. IV) in GC pa-
tients. However, there was no significant difference between
the expression level of MEG3 and other clinicopathologiccharacteristics, including gender, age, venous invasion, pos-
ition, borrmann typing, pT stage, pN stage in GC (data not
shown). These results indicated that the dysregulation of
MEG3 in GC patients might suggest a potential tumor sup-
pressor role of MEG3 in GC tumorigenesis.
MEG3 inhibits GC cell proliferation, migration and
invasion
To test whether MEG3 play an important role in gastric
carcinogenesis, the level of MEG3 in GC cell lines was
first measured and the results showed that MEG3 was
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7901 and MKN-45 (Fig. 1e). Of them, MGC-803 and
HGC-27 were selected to study the function of MEG3. A
construct containing MEG3 transcripts (pCMV-MEG3)
was transfected into the HGC-27 and MGC-803 cells and
the efficiency of MEG3 overexpression was subsequently
confirmed by q-PCR analysis (Fig. 2a). The intracellular
level of MEG3 was enhanced by 50-fold and 40-fold in
HGC-27 and MGC-803 cells treated with pCMV-MEG3
than the empty vector pCMV6, respectively (Fig. 2a). Ac-
cordingly, The proliferation of transfected MGC-803 andFig. 2 The functional analysis of MEG3 in GC cells. a YAP1 level were detec
pCMV6 empty vector by RT-qPCR; b Cell proliferation assay of HGC-27 and M
c Flow cytometry was applied to examine the apoptosis of HGC-27 and MGC
apoptosis markers (FITC-Annexin V and PI). In the apoptosis map, FITC-Annexi
apoptosis, and FITC-Annexin V−/PI− indicates normal live cells. d Wound hea
pCMV-MEG3 or pCMV6, The relative ratio of wound closure per field w
cells after treatment with pCMV-MEG3 or pCMV6, The relative ratio of invas
data are presented as the mean ± SEM, and the error bars represent the stand
**p < 0.01HGC-27 cells was measured by using CCK-8 assay. Ec-
topic expression of MEG3 led to significant decrease in
cell proliferation in both HGC-27 and MGC-803 cells
(Fig. 2b). Furthermore, we examined the effects of MEG3
on the apoptosis of HGC-27 and MGC-803 cells receiving
MEG3 or not with flow cytometry. The flow cytometry re-
sults showed that MEG3 increased the early and late
apoptosis of HGC-27 and MGC-803 cells compared to
control group (Fig. 2c).
Based on the correlation between MEG3 expression
and metastatic factors, we proposed that this lncRNAted in HGC-27 and MGC-803 cells after treatment with pCMV-MEG3 or
GC-803 cells after treatment with si-YAP1 or control by using CCK-8;
-803 cells after treatment with pCMV-MEG3 or pCMV6 and stained with
n V+/PI+ indicates late apoptosis, FITC-Annexin V+/PI− indicates early
ling assays of HGC-27 and MGC-803 cells after treatment with
as shown in the right; e Transwell analysis of HGC-27 and MGC-803
ive cells per field was shown right. For all quantitative results, the
ard deviation obtained from three independent experiments. *p < 0.05;
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and invasion of GC cells. To test this hypothesis, cell mi-
gration and invasion assays were performed in HGC-27
and MGC-803 cells transfected with pCMV-MEG3 or
pCMV6. As a result, the wound healing assay showed that
cell migration was inhibited in MEG3-overexpressed GC
cells compare to the controls (Fig. 2d). Moreover, trans-
well invasion assay indicated a significant reduction in cell
invasiveness after pCMV-MEG3 transfection into both
HGC-27 and MGC-803 cells (Fig. 2e). Taken together,
these results suggest that MEG3 may act as a tumor sup-
pressor through inhibiting cell proliferation, migration
and invasion, and promoting cell apoptosis in GC.Fig. 3 The interaction of MEG3 with miR-181. a The upper panel: schemati
lower panel: the prediction for miR-181 s binding sites on MEG3 transcript.
seed sequences. b Luciferase activity in HGC-27 cells cotransfected with m
containing nothing, wild type MEG3 or diverse mutant MEG3 as indicated.
renilla luciferase activity. c MS2-RIP followed by miRNA RT-qPCR to detect m
results, the data are presented as the mean ± SEM, and the error bars repre
experiments. *p < 0.05; **p < 0.01MEG3 is physically associated with miR-181 family
The ceRNA hypothesis posits that specific lncRNA can
function as sinks for pools of active miRNAs, function-
ally liberating mRNA transcripts targeted by that set of
miRNAs. To determine whether MEG3 can operate as a
ceRNA, we used the webserver lnCeDB (http://gyanxet-
beta.com/lncedb/) to predict potential lncRNA-miRNA in-
teractions. Among the results, we found 4 miR-181 family
binding sites scattering the MEG3 transcripts, suggesting
its ceRNA potential for miR-181 s (Fig. 3a). Subsequently,
we constructed a series of luciferase reporters containing
the wild type MEG3 (pMIR-MEG3-WT), or mutant MEG3
with mutations of single (pMIR-MEG3-MUT1, 2, 3, 4) orc outlining the predicted binding sites of miR-181 s on MEG3. The
The red nucleotides are the complementary sequences to miR-181
iR-181a mimic (25 nM) mimic control (25 nM) and luciferase reporters
Data are presented as the relative ratio of firefly luciferase activity to
iR-181a endogenously associated with MEG3. For all quantitative
sent the standard deviation obtained from three independent
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MUT1-4). The miR-181 family contains four miRNAs
(miR-181a/b/c/d), which are transcribed from three sepa-
rated gene loci. Here, we mainly focused on miR-181a to
further investigate the interaction between MEG3 and miR-
181a in GC cells. We found that transfection of HGC-27
cells with miR-181a mimic reduced the luciferase activities
of the MEG3-WT reporter vector but not empty vector or
all miR-181 site mutant reporter vector (Fig. 3b), suggesting
the binding of miR-181a to these sites. To further validate
the direct interaction between miR-181a and MEG3 at en-
dogenous levels, we performed an RNA immunopre-
cipitation (RIP) analysis to pull down endogenous
miRNAs associated with MEG3. The precipitated
miRNAs were q-PCR analyzed and results showed
that the MEG3 RIP (MEG3-WT-MS2) in HGC-27
cells was significantly enriched for miR-181a com-
pared to the empty vector (MS2) and MEG3 with
mutations in all four miR-181a targeting sites (MEG3-
MUT1-4-MS2), supporting that miR-181a was bona
fide MEG3-targeting miRNAs (Fig. 3c). These data
demonstrated that miR-181a could bind to MEG3 and
MEG3 could function as a ceRNA in GC cells.
miR-181a function as an oncogene in GC
Based on above findings, miR-181a may also play a role
in gastric carcinogenesis. We first investigated miR-181a
level in above 50 pairs of clinic GC tissue and matched
adjacent normal tissue samples. In contrast to MEG3,
miR-181a was dramatically increased in GC tissue com-
pared with adjacent normal tissues (Fig. 4a), indicating
its oncogenic role in GC. We then used HGC-27 and
MGC-803 cells to analyze the role of miR-181a. RT-
qPCR was first used to measure the level of miR-181a
after transfection and showed that the level of miR-181a
was reduced to ~40 % and ~30 % in miR-181a inhibitor-
transfected HGC-27 and MGC-803 cells (Fig. 4b). Ac-
cordingly, the CCK-8 proliferation assay in the same
cells indicated that cell growth was suppressed after
transfection with miR-181a inhibitor (Fig. 4c). Reduced
miR-181a expression also decreased the early and late
apoptosis of HGC-27 and MGC-803 cells compared to
control group (Fig. 4d).
Additionally, the wound healing assay showed that cell
migration was inhibited in miR-181a inhibitor-
transfected HGC27 and MGC-803 cells compare to the
inhibitor control-transfected ones (Fig. 4e), suggesting
the stimulating effects of miR-181a on tumor cell migra-
tion. To detect whether miR-181a possesses the ability
to inhibit cell invasion, transwell invasion assay was per-
formed. As expected, there was significant reduction in
cell invasiveness after miR-181a inhibitor transfection in
both HGC-27 and MGC-803cell lines (Fig. 4 f ). Taken
together, these results indicated the oncogenic roles ofmiR-181a in GC cells, which was opposite to its ceRNA
MEG3.
MEG3 ceRNA activity regulates Bcl-2 expression
The oncogenic role of miR-181a promoted us to study
its mechanism in gastric carcinogenesis. Studies have re-
ported that miR-181 targets multiple Bcl-2 family mem-
bers in astrocytes [24]. To validate whether miR-181a
targets Bcl-2 in GC, immunoblotting assay was carried
out and showed that Bcl-2 was about 2-fold higher in
HGC-27 cells transfected with miR-181a inhibitor com-
pared with the control (Fig. 5a). Because MEG3 shared
regulatory miR-181a with Bcl-2 mRNA, we wondered
whether MEG3 could modulate Bcl-2 in GC cells. As
excepted, overexpression of wild type MEG3 (pCDNA-
MEG3-WT), but not the mutant (pCDNA-MEG3-
MUT1-4), increased Bcl-2 transcript (Fig. 5b) and protein
levels in HGC-27 cells (Fig. 5c). Furthermore, ectopic ex-
pression of miR-181a upon pCDNA-MEG3-WT transfec-
tion abrogated this increase (Fig. 5b, c). All these results
suggest an important role of MEG3 in modulating Bcl-2
by competitively binding miR-181a.
Discussion
Maternally expressed gene 3 (MEG3) is an imprinted
gene belonging to the imprinted DLK1–MEG3 locus lo-
cated at chromosome 14q32.3 in human genome. Its
mouse ortholog, Meg3, also known as gene trap locus 2
(Gtl2), is located at distal chromosome 12 [25]. Mice
carrying the maternal deletion of the Meg3 region died
perinatally and had major skeletal muscle defects. MEG3
is expressed in many normal tissues, and the loss of
MEG3 expression has been found in various types of hu-
man tumors, including in 25 % of neuroblastomas, 81 %
of hepatocellular cancers, and 82 % of gliomas [26, 27].
However, the involvement of MEG3 in gastric cancer
has not been reported. Our findings indicated that
MEG3 was down-regulated in GC tissues, and a lower
level of MEG3 was associated with tumor stage and me-
tastasis. Functional analysis confirmed the pleiotropic ef-
fects of MEG3 on GC cell proliferation, migration and
invasion. Therefore, lncRNA MEG3 was determined as a
novel tumor suppressor in human GC.
Although a vast set of lncRNA transcripts are differen-
tially expressed during development where many of
them play critical roles, most of them have not yet been
studied in mechanistic details. Till now, a majority of
the lncRNAs have been linked with epigenetic modula-
tion of gene expressions, they can also regulate gene ex-
pression by transcriptional or post transcriptional modes.
In recent years it has been discovered that endogenous
lncRNAs can influence post-transcriptional regulation by
interfering with the miRNA pathways, by acting as com-
peting endogenous RNAs (ceRNAs) [28–30]. These
Fig. 4 The functional analysis of miR-181a in GC cells. a Relative miR-181a expression level in GC tissues and adjacent normal regions; The
expression of level of miR-181a was detected in 50 GC patients by RT-qPCR. b miR-181a level were detected in HGC-27 and MGC-803 cells after
treatment with miR-181a inhibitor (25 nM) or inhibitor control (25 nM) by RT-qPCR; c Cell proliferation assay of HGC-27 and MGC-803 cells after
treatment with miR-181a inhibitor or inhibitor control by using CCK-8; d Flow cytometry was applied to examine the apoptosis of HGC-27 and
MGC-803 cells after treatment with miR-181a inhibitor or inhibitor control and stianed with apoptosis markers (FITC-Annexin V and PI). In the
apoptosis map, FITC-Annexin V+/PI+ indicates late apoptosis, FITC-Annexin V+/PI− indicates early apoptosis, and FITC-Annexin V−/PI− indicates
normal live cells. e Wound healing assays of HGC-27 and MGC-803 cells after treatment with miR-181a inhibitor or inhibitor control, The relative
ratio of wound closure per field was shown in the right; f Transwell analysis of HGC-27 and MGC-803 cells after treatment with miR-181a inhibitor or
inhibitor control, The relative ratio of invasive cells per field was shown right. For all quantitative results, the data are presented as the mean ± SEM,
and the error bars represent the standard deviation obtained from three independent experiments. *p < 0.05; **p < 0.01
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as miRNA sponges to control endogenous miRNAs avail-
able for binding with their target mRNAs, thus reducing
the repression of these mRNAs [29]. It also suggests that
these ceRNAs are implicated in many biological processes
and the disruption of the equilibrium of ceRNAs and miR-
NAs can be critical for ceRNA activity and promotion of
diseases like cancer. For example, lncRNA PTEN-P1 could
block miR-19b and miR-20a from binding to PTEN tumor
suppressor in prostate cancer, glioblastoma, and melanoma,and disruption in the network leads to tumorigenesis in
many cases [28, 31]. HULC lncRNA also acts as ceRNA of
the protein coding gene PRKACB that induces activation of
CREB to modulate self-regulation in hepatocellular carcin-
oma [32]. In a recent study, lncRNA-activated by TGF-b
(lncRNA-ATB) was upregulated in hepatocellular carcin-
oma metastases and associated with poor prognosis
[33]. lncRNA-ATB upregulated ZEB1 and ZEB2 by
competitively binding the miR-200 family and then
induced EMT and invasion [33]. Additionally, Hmga2
Fig. 5 Regulation of Bcl-2 by MEG3. a Immunoblot analysis of Bcl-2 in HGC-27 cells transfected with miR-181a inhibitor or inhibitor control; An
unrelated protein GAPDH was used as the control. b The expression of MEG3 and Bcl-2 mRNA in HGC-27 cells transfected with empty vector,
wild type MEG3 or mutant MEG3 as indicated; c Immunoblot analysis of Bcl-2 protein in HGC-27 cells transfected with empty vector, wild type
MEG3 or mutant MEG3 as described in B; d A Schematic model of MEG3/miR-181/Bcl-2 cascade in gastric carcinogenesis. For all quantitative
results, the data are presented as the mean ± SEM, and the error bars represent the standard deviation obtained from three independent experiments.
*p< 0.05; **p< 0.01
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gene and as a ceRNA dependent upon the presence of let-
7 sites [34]. Thus, The intricate networks of ceRNAs in
cells are a fascinating new subject of study for researchers
working towards understanding the language of RNA mol-
ecules and gene expression networks in tumorigenesis.
In this study, we report that lncRNA MEG3 inhibits GC
cell proliferation, migration and invasion by competitively
binding the miR-181 family, upregulating Bcl-2, and then
suppressing gastric carcinogenesis (Fig. 5d). The dysregu-
lation of MEG3 has been reported in many cancer types
and its tumor suppressor activity was mediated by inter-
action with either p53-dependent transcription, or Rb-
related pathways. Our studies revealed a novel ceRNA
activity of MEG3 in human GC cells. Although much
of MEG3 ceRNA activity is driven by overexpression
of Bcl-2 in GC, there are likely to be additional MEG3
ceRNA targets to be found in future studies.
Conclusions
Taken together, our research demonstrated that MEG3
acted as a key regulator in human gastric carcinogenesis
and revealed roles of MEG3 in regulating miR-181-Bcl2axis. The findings of this study have significant implica-
tions regarding our understanding of GC pathogenesis.
Moreover, the pleiotropic effects of MEG3 on GC tumori-
genesis suggest that it could be an effective target for anti-
neoplastic therapies.
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